COO - Educational Analysis * US Equities
Educational Analysis * US Equities

COO

Earnings behavior, post-earnings drift, and the gap between consensus and the market's real expectation - the educational primer before you look at the institutional verdict.

Educational content only - not investment advice. Nothing on this page is a recommendation to buy or sell any security. Historical patterns do not predict future outcomes. Consult a licensed financial advisor before making any trading decision.
Published byGamma QC editorial
TickerCOO
CategoryEducational primer
Last reviewedNovember 16, 2026
You're viewing an older edition of this page.Read the latest edition →

Business Profile & Competitive Position

The Cooper Companies, Inc. (COO) operates in the Healthcare sector, specifically the Medical - Instruments & Supplies industry. It is a global medical device company based in San Ramon, California, and it reports through two distinct segments. CooperVision develops, manufactures, and markets single-use, two-week, monthly, and specialty contact lenses, including silicone hydrogel lenses, orthokeratology lenses, scleral lenses, and the MiSight 1 day myopia-management lens. CooperSurgical offers more than 600 products and services in fertility and women’s health, spanning gynecology, obstetrics, contraception, labor and delivery, cord blood and tissue storage, IVF support, donor gametes, cryopreservation, and genomic services.

The company’s reach is genuinely global: products are sold in over 130 countries, touching more than 50 million lives annually, and it employs roughly 500 R&D professionals across both segments. The MiSight 1 day lens is a differentiated asset because it is the only contact lens approved by the FDA, Chinese NMPA, and Japanese MHLW to slow the progression of myopia in age-appropriate children. That regulatory trifecta creates a real, if narrow, competitive edge.

Still, the margin and return data temper the moat story. Net margin of 13.5% is solid for a healthcare device maker, but ROE of 6.9% is modest and would generally fall below the long-run cost-of-equity threshold most analysts use. Together, these figures suggest a business with stable pricing and decent scale, but not one that is compounding capital at an elite rate. The moat looks more like a collection of product niches and regulatory approvals than a wide, capital-light franchise.

Financial Posture

COO’s current financial profile is that of a mid-cap, lower-volatility healthcare name. Market capitalization is $11.9 billion, the P/E ratio is 21.4, and the stock’s beta is 0.82. At the current snapshot, the share price is $62.65, with the 50-day EMA at $61.31 and an RSI of 56.6.

A net margin of 13.5% and a P/E of 21.4x imply the market is paying a reasonable, if not cheap, multiple for consistent, defensive earnings. The sub-1.0 beta fits that narrative: relative to the broader market, COO’s stock has tended to move less dramatically on headline risk. The ROE of 6.9% is the main blemish in the profitability picture. It signals that, even after factoring in any leverage benefit, the company is not generating high shareholder returns on its equity base. That does not make the balance sheet fragile, but it does frame COO more as a steady-paying healthcare operator than a high-return compounder.

Strategic Priorities & Outlook

The company’s most recent 10-K filing lays out a set of practical, segment-specific priorities rather than a grand top-down pivot.

These priorities read as an effort to convert existing product strength—especially MiSight and the fertility/women’s health platform—into broader market share. The emphasis on distribution and practitioner education also signals that growth will require ongoing capital and operating investment rather than a quick margin extraction story.

Macro & Geopolitical Exposure

Because COO sits in the Medical - Instruments & Supplies industry, its macro exposures are those typical of global medical-device companies rather than generic consumer or tech names.

Regulatory and reimbursement risk is central. Approvals from bodies like the FDA, China’s NMPA, and Japan’s MHLW are prerequisites for the most differentiated products, while pricing and reimbursement decisions by governments and private insurers influence adoption. Currency exposure is also meaningful: with sales in over 130 countries, a stronger U.S. dollar can compress reported revenue and earnings even when local demand is steady. Supply chain inputs—specialty polymers, packaging, sterilization, and logistics—can create cost volatility, especially for single-use lenses and surgical kits. On the demand side, demographic trends such as rising myopia rates and delayed childbearing support long-term volume growth, but a soft macro environment can press elective fertility spend and discretionary eye-care purchases in the near term.

Recent Developments

The most visible recent headlines for COO are all investor-notice releases tied to a securities investigation, not product or financial updates.

These releases are solicitation notices from a plaintiff-side law firm and do not establish that any violation occurred. They do, however, create headline risk and can weigh on sentiment, particularly when they cluster in the days before an earnings report. Traders should treat them as a distraction-from-investor-returns signal rather than a fundamental verdict on the business.

Earnings Behavior & Post-Earnings Drift

COO’s earnings track record is statistically unusual because the headline beat rate and the post-release price direction do not line up in the way most investors expect.

Over the last eight reported quarters, COO has beaten estimates 8 out of 8 times (100%), with an average earnings surprise of 4.2%. Yet the average 5-day price move after earnings is -2.34%, with the drift classified as “down.” That means even when the company has delivered upside, the stock has often failed to follow through to the upside over the following week.

The last four quarters illustrate the disconnect clearly:

The takeaway is not that COO misses expectations; it almost never does. The takeaway is that “beat” and “pop and hold” are not the same thing. Post-earnings price action appears to depend heavily on guidance tone, forward-year revisions, or whether the current beat was already priced in. The next report is scheduled for December 3, 2026, after the close, with the current consensus EPS estimate at $1.07. Even if COO continues its 100% beat streak, history says traders should watch the five-day drift, not just the next-day gap.

Frequently Asked Questions

What are the two main business units at The Cooper Companies?

COO operates through CooperVision, which sells contact lenses and specialty eyecare products, and CooperSurgical, which provides fertility and women’s health devices, services, and storage solutions.

Why has COO stock sometimes fallen after beating earnings estimates?

The data shows an 8-for-8 beat rate and a 4.2% average surprise over the last eight quarters, but the average 5-day post-earnings drift is -2.34%. That disconnect suggests price action is driven more by guidance, valuation reset, or how much of the beat was already priced in, rather than the beat itself.

What are COO’s stated strategic priorities?

According to its most recent 10-K, CooperVision is focused on global product penetration, distribution and packaging investment, and myopia-management education, while CooperSurgical is pursuing investment and strategic transactions to expand its integrated fertility and women’s health platform.

For a deeper dive into how institutional analysts and smart-money flows are interpreting COO ahead of the December 3 report, readers should review the full institutional verdict on the platform.

Real Data - Gamma QC Earnings IntelligenceAs of Nov 16, 2026
The Cooper Companies, Inc. · Healthcare / Medical - Instruments & Supplies
$11.9BMarket cap
21.4P/E
13.5%Net margin
6.9%ROE
100%Beat rate, last 8Q
4.2%Avg EPS surprise
-2.34%Avg 5-day move after earnings
2026-12-03Next earnings
ReportedActualEstimateSurprise1D Move5D Move
2026-09-09$1.15$1.12+2.7%-14.67%-13.97%
2026-06-04$1.21$1.1+10%+8.58%+8.85%
2026-03-05$1.1$1.03+6.8%-4.55%-10.82%
2025-12-04$1.15$1.11+3.6%+5.67%+6.59%
2025-08-27$1.1$1.07+2.8%--
2025-05-29$0.96$0.928+3.4%--

Previous COO editions

Beyond the primer

Get the institutional verdict on COO

Seven-seat 21-ERT council. Pre-print forecast signed before the earnings release. Post-print grade, published in public. Every verdict sealed with a cryptographic receipt.

Read the COO verdict at Gamma QC
$49 Pro / $249 RIA * gammaqc.com

Verify authenticity

Every Gamma QC verdict is signed with a cryptographic receipt at issuance. Independently verify any published verdict at attest.gammaqc.com. This educational primer is content-only and not itself signed; the institutional verdict at the link above is.